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Abstract
Signal transducer and activator of transcription STAT5 is an essential mediator of cytokine, growth factor and hormone
signaling. While its activity is tightly regulated in normal cells, its constitutive activation directly contributes to oncogenesis
and is associated to a number of hematological and solid tumor cancers. We previously showed that deacetylase inhibitors
can inhibit STAT5 transcriptional activity. We now investigated whether the dietary chemopreventive agent sulforaphane,
known for its activity as deacetylase inhibitor, might also inhibit STAT5 activity and thus could act as a chemopreventive
agent in STAT5-associated cancers. We describe here sulforaphane (SFN) as a novel STAT5 inhibitor. We showed that SFN,
like the deacetylase inhibitor trichostatin A (TSA), can inhibit expression of STAT5 target genes in the B cell line Ba/F3, as
well as in its transformed counterpart Ba/F3-1*6 and in the human leukemic cell line K562 both of which express a
constitutively active form of STAT5. Similarly to TSA, SFN does not alter STAT5 initial activation by phosphorylation or
binding to the promoter of specific target genes, in favor of a downstream transcriptional inhibitory effect. Chromatin
immunoprecipitation assays revealed that, in contrast to TSA however, SFN only partially impaired the recruitment of RNA
polymerase II at STAT5 target genes and did not alter histone H3 and H4 acetylation, suggesting an inhibitory mechanism
distinct from that of TSA. Altogether, our data revealed that the natural compound sulforaphane can inhibit STAT5
downstream activity, and as such represents an attractive cancer chemoprotective agent targeting the STAT5 signaling
pathway.
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Introduction
With an estimated 32.6 million people living with cancer and
8.2 million deaths attributed to cancer worldwide in 2012 [1],
cancer prevention has become a public health priority. About a
third of all cancer cases are thought to be associated to behavioral
and dietary risks and are thus considered preventable [2,3].
Dietary chemoprevention has gained considerable interest over
the past few years as a simple and efficient approach to lower
overall cancer risk and reduce cancer incidence and mortality
[2,3]. For dietary chemoprevention strategies to be successful
however, a number of conditions have to be met. First, the
beneficial nutritional compound must be provided by easily
accessible food. Second, its consumption must lead to detectable
and reasonable concentrations in the blood while being properly
distributed throughout the body to reach target tissues. Finally,
since cancer is a multistep process from early carcinogenesis to
tumor initiation, promotion and progression, the ability of the
dietary molecule to target multiple pathways simultaneously would
be advantageous. The isothiocyanate sulforaphane (SFN) found in
abundance in cruciferous vegetables such as broccoli fulfill these
requirements and is thus viewed as an ideal cancer chemopre-
ventive agent [4–6].
Chemopreventive agents are usually classified as blocking and
suppressive agents. Blocking agents inhibit phase I enzymes that
convert pro-carcinogens into carcinogens and/or induce phase II
enzymes that stimulate the detoxification and elimination of
carcinogens. Suppressive agents inhibit malignant transformation
by targeting pathways controlling cell proliferation, differentiation
and survival [7]. Sulforaphane was initially identified as a potent
inducer of phase II detoxification enzymes [4], via the Keap1/
Nrf2 pathway and as a result of SFN activity as an electrophile
reacting with protein thiols [8–12]. SFN was thereafter shown to
inhibit the activity of phase I enzymes and act as a cancer
suppressive agent by modulating signaling pathways involved in
cell growth, apoptosis, inflammation and angiogenesis [5,6].
Interestingly, SFN chemoprotection properties have not only been
demonstrated in vitro but also in vivo, both in animal models and in
humans [5,6]. Several clinical trials investigating the beneficial role
of SFN in cancer therapy and prevention are currently ongoing
worldwide [13].
Among the cancer suppression functions of SFN, its activity as a
histone deacetylase inhibitor is of particular interest for cancer
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prevention and therapy [14,15]. Deacetylase inhibitors indeed
represent a promising new class of anti-cancer drugs. The
deacetylase inhibitor suberoylanilide hydroxamic acid SAHA
(Vorinostat) has been approved for the treatment of cutaneous T
cell lymphoma and several other deacetylase inhibitors are being
currently evaluated in clinical trials for the treatment of various
types of cancers [16]. Inhibition of deacetylase activity by SFN was
demonstrated in cancer cell lines [17,18], mice [19,20], and
human subjects [19]. Treatment with SFN results in an increase in
acetylated histone H3 and H4 both globally and locally at
promoters of genes such as the cell cycle regulator p21 [17,18,20].
We previously showed that the deacetylase inhibitors sodium
butyrate, trichostatin A (TSA) and suberoylanilide hydroxamic
acid (SAHA) inhibit IL-3-mediated STAT5 transcriptional activity
in the mouse pro-B cell line Ba/F3 [21]. STAT5 (signal transducer
and activator of transcription 5) is a key regulator of cell
proliferation, differentiation and survival [22,23]. Following
stimulation by cytokine, growth factor or hormone, inactive
cytosolic STAT5 is phosphorylated by the tyrosine kinase JAK2.
Phosphorylated STAT5 then dimerizes, translocates into the
nucleus, binds to specific DNA binding sites, and activates
transcription of STAT5 target genes (e.g. Cis, c-Myc, Pim-1, Osm,
Socs-1) [22,24–26]. STAT5 activity is regulated at multiple levels,
through post-translational modifications, protein-protein interac-
tions and tetramerization [22,27–34]. Attenuation of the pathway
is tightly regulated via a negative feedback loop mediated by
proteins of the SOCS family (CIS, SOCS-1/-3) as well as via
dephosphorylation [35,36]. Improper activation, in particular
constitutive activation of STAT5 (caSTAT5) is associated with a
broad range of blood and solid tumor cancers [35–37].
Constitutive activation of STAT5 directly contributes to onco-
genesis through stimulation of cell proliferation and prevention of
apoptosis [25,35–38] and is frequently associated to epigenetic
silencing of negative regulators of the STAT5 signaling pathway
[39–43].
STAT5 therefore represents a target of choice for both cancer
therapy and prevention [37,44–47]. A number of JAK/STAT
inhibitors have been reported. Most of them, whether natural or
synthetic small-molecules, target the upstream activating kinase
JAK2 [44–56], thus inhibiting JAK2-dependent downstream
pathways such as MAPK and AKT in addition to STAT5
[57,58]. Fewer inhibitors have been described that target STAT5
protein itself and its transcriptional activity [21,59–64]. We
showed that inhibition of STAT5 activity by deacetylase inhibitors
takes place at the transcriptional level. We demonstrated that
deacetylase inhibitors target STAT5-mediated transcriptional
initiation by preventing recruitment of the basal transcription
machinery, without affecting STAT5 activation (phosphorylation)
and binding to DNA [21,65].
Given the central role of STAT5 as a relevant target for cancer
chemoprevention and its sensitivity to deacetylase inhibitors, we
tested the hypothesis that sulforaphane (SFN) might act as an
inhibitor of STAT5 activity. We show here, to the best of our
knowledge for the first time, that SFN, similarly to the deacetylase
inhibitor TSA, inhibits STAT5 activity in both normal and
caSTAT5-transformed cells. Like TSA, SFN treatment inhibited
STAT5-mediated induction of target genes at the RNA level,
without affecting STAT5 initial activation (phosphorylation) and
DNA recognition. By contrast to TSA however, this inhibitory
effect was not associated with changes in global histone acetylation
levels, nor did it affect histone acetylation at specific target genes,
thus suggesting a deacetylase-independent effect. Our data
uncover STAT5 as a novel molecular target of SFN, hence
confirming this dietary isothiocyanate as a potent anti-cancer
agent.
Materials and Methods
Chemicals
Dimethyl sulfoxide (DMSO) and trichostatin A (TSA) were
purchased from SIGMA (D2650 and T8552 respectively). R,S-
Sulforaphane (SFN) was from LKT Laboratories (S8044) and
Imatinib was from Cayman Chemical (No. 13139). Compounds
were dissolved in DMSO at a final concentration of 1 mM (TSA),
5 mM (Imatinib) or 100 mM (SFN).
Cell lines and drug treatments
All cell lines were grown in RPMI 1640 (PAN-Biotech P04-
16500) supplemented with 10% heat-inactivated fetal calf serum
(FCS; PAN-Biotech), penicillin/streptomycin (PAN-Biotech)
(thereafter designated as RPMI-based medium) and cultivated at
37uC under 5% CO2 in a humidified incubator. K562 cells (a kind
gift from Daniela Ma¨nnel, University of Regensburg, Germany;
[66]) were maintained in RPMI-based medium. The non-
tumorigenic immortalized interleukin-3 (IL-3)-dependent mouse
pro-B cell line Ba/F3 (a kind gift from Jacqueline Marvel, IFR 128
BioSciences Gerland-Lyon Sud, France; [67]) was grown in
RPMI-based medium supplemented with 2 ng/mL rmIL-3
(ImmunoTools). The Ba/F3-1*6 cell line (clone F7) stably
expressing the constitutively active mouse STAT5A-1*6 mutant
[68] was generated as previously described [56] and grown in
RPMI-based medium supplemented with 500 mg/mL G418.
For cytokine stimulation of Ba/F3 cells, cells were washed twice
in RPMI 1640 and rested in RPMI-based medium for 9 to
12 hours before addition of 5 ng/mL IL-3 for 30-60 minutes, as
indicated in the figure legends. Inhibitor (TSA, SFN) or vehicle
(DMSO) was added 30 minutes prior to IL-3 stimulation. Ba/F3-
1*6 and K562 cells were treated for 60-90 minutes with TSA, SFN
or DMSO (vehicle), as indicated. With the exception of the cell
viability assays, DMSO final concentration was adjusted to 0.1%
(cytotoxicity assay) or to 0.02% (other assays) in all conditions.
Gene expression analysis by quantitative RT-PCR
Quantitative RT-PCR was performed as previously described
[56]. Data were normalized to mouse S9 ribosomal (Ba/F3 and
Ba/F3-1*6 cell lines) or human Lamin A/C (LMNA) (K562 cell
line) mRNAs, and expressed as relative mRNA levels, as
previously described [21,24,56,65]. Mouse- and human-specific
real-time PCR primers used in this study have been already
reported [21,24,56,69]. Data are mean 6SD of the quantitative
PCR, performed in either duplicate or triplicate, and are
representative of at least three independent experiments. Raw
data (CT values) are available in File S1.
Cytotoxicity assays
WST-1 assays (11 644 807 001, Roche) were performed as
recently reported [56] to monitor changes in metabolically active
mitochondrial dehydrogenases as a result of TSA- or SFN-induced
cytotoxicity. Briefly, rested Ba/F3 and growing Ba/F3-1*6 and
K562 cells were pre-treated for 30 minutes with the indicated
concentrations of TSA, SFN or DMSO (vehicle), WST-1 reagent
was added to the cells either alone (Ba/F3-1*6, K562) or together
with IL-3 (Ba/F3), and absorbance was measured after 90 minutes
(maximal duration of inhibitor treatment in our gene expression
assays) in a microplate reader (Mithras LB 940, Berthold
Technologies; 450/620 nm). A positive control for no mitochon-
drial enzyme activity (1% Triton X-100) was included in every
STAT5 Nuclear Activity Is Inhibited by Sulforaphane
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experiment. Data are expressed as a percentage of cytotoxicity
relative to DMSO (vehicle). Data shown are representative of two
independent experiments. Raw data (OD 450/620 nm) are
available in File S1.
Cell viability assays
The number of living and dead cells was evaluated by Trypan
Blue exclusion after 24 and 48 hours of TSA or SFN treatment, as
previously described [56]. Viable cell number for each treatment,
reflecting cell proliferation and survival, is expressed as a function
of time. Data shown are representative of at least two to three
independent experiments.
Quantitative chromatin immunoprecipitation (ChIP)
assays
Chromatin immunoprecipitation was performed as previously
described [56]. Antibodies specific for STAT5, RNA polymerase
II, acetylated histone H3 (Ac-H3) and acetylated histone H4 (Ac-
H4) have been reported [21]. ChIP grade anti-histone H3
antibody (total H3) was from abcam (ab1791). Real-time PCR
primers specific for the STAT5 binding sites and for the
transcription start site (tss) of the mouse Cis gene (amplicons A
and B) have been described [21]. Forward and reverse real-time
PCR primers specific for amplicons C to H along the open reading
frame of the mouse Cis gene were respectively: amplicon C, 59-
GGACTTCGAGTGGTGTGCCTA-39 and 59-GGCTCCG-
TTTCCCTATCCA-39; amplicon D, 59-CATTCCTCCGTCC-
CAGGTC-39 and 59-ACCTCAGGCTGGCTTCCTAAG-39;
amplicon E, 59-AATTTTCGGACTCTTCGGCA-39 and 59-
CACCCAAGAAAGGAAGGCAG-39; amplicon F, 59-CAGCT-
CCTAACCACCCCTGTT-39 and 59-ACTGGCTGGGAAAG-
GCAAC-39; amplicon G, 59-GAGGACACTGCCTTCCCTCA-
39 and 59-AAGCTTCTACCCACTCCGGC-39; amplicon H, 59-
TACCCCTTCCAACTCTGACTGAGC-39 and 59-TTCCCT-
CCAGGATGTGACTGTG-39. Real-time PCR primers specific
for the STAT5 binding sites and for the tss of the mouse Osm gene
(amplicons I and J) have been described [21,56]. Forward and
reverse real-time PCR primers specific for the mouse p21 proximal
promoter region (2120/261 relative to the tss; amplicon K) were
59-GAGGGCGGGCCAGCGAGTC-39 and 59-CTCAGAGG-
CAGGACCAACCCACTC-39. Data are mean 6SD of the
quantitative PCR, performed in either duplicate or triplicate,
and are representative of at least two to three independent
experiments. Raw data (CT values) are available in File S1.
Protein analysis by Western blot
Whole-cell Brij protein lysis (analysis of STAT5 activation) and
immunoblotting were performed as described [21,56,69]. Anti-
bodies used for the detection of pSTAT5, STAT5A, STAT5B,
STAT5A+B, a-tubulin, Anti-Rabbit and Anti-Mouse IgG-Perox-
idase, as well as their respective working dilutions, have been
reported [56].
Whole-cell protein lysis for the analysis of histone acetylation
was performed as follows. Equal number of growing Ba/F3 cells
cultured in the presence of 0.2 mM TSA or 10 mM SFN were
harvested at the indicated times and resuspended in Freeze-Thaw
lysis buffer (600 mM NaCl, 20 mM Tris-HCl pH 8.0, 20%
Glycerol, protease inhibitors). Upon three freeze-thaw cycles,
whole-cell lysates were treated with DNase I (0.1 mg/ml final in the
presence of 5 mM MgCl2) for 45 minutes at +4uC, adjusted to 16
Laemmli buffer containing b-mercaptoethanol and heated at 95uC
for 10 minutes. Denatured samples were centrifuged 15 minutes at
maximum speed to eliminate cell debris, before loading equal
volumes (corresponding to equal cell number) on a 15% SDS-
PAGE for Western blot analysis. Antibodies used for the detection
of histone proteins were: Anti-acetylated histone H3 (06-599,
Upstate/Millipore; 1:5000), Anti-acetylated histone H4 (06–866,
Upstate/Millipore; 1:2000) and Anti-histone H3 (ab1791, Abcam;
1:3000).
Apparent molecular weight of detected proteins was as
predicted by the antibody manufacturers, i.e. 90 kDa for STAT5
(with STAT5A running slightly slower than STAT5B in SDS-
PAGE), 55 kDa for a-tubulin, 17 kDa for histone H3 and 11 kDa
for histone H4. Immunoblots shown are representative of at least
three independent experiments.
Results
Sulforaphane treatment inhibits IL-3-mediated
expression of STAT5 target genes in Ba/F3 cells
The effect of sulforaphane (SFN; Figure 1A) on the STAT5
signaling pathway was investigated in the IL-3-dependent Ba/F3
cell line. Expression of the STAT5 target genes Cis, Osm and c-Myc
upon IL-3 stimulation was monitored by quantitative RT-PCR in
cells pre-treated with increasing amount of SFN (0.4-10 mM) or
with 0.2 mM trichostatin A (TSA). TSA was used as a reference
inhibitor throughout this study (Figure 1A), in accordance with our
previous observation that TSA inhibits STAT5-mediated tran-
scription [21,65]. Similarly to TSA, SFN treatment was able to
inhibit IL-3-mediated induction of the STAT5 target genes Cis,
Osm and c-Myc in a dose-dependent manner, while expression of
the housekeeping gene 36b4 remained unaffected (Figure 1B).
We next verified that the inhibitory effect of SFN was not the
result of cytotoxicity. WST-1 assays were performed in IL-3-
stimulated Ba/F3 cells using concentrations of 0.1–100 mM SFN
(Figure 2A). No cytotoxicity was detected up to 10 mM SFN while
40% toxicity was noted in the presence of 100 mM (Figure 2A).
SFN was used thereafter at concentrations not exceeding 10–
20 mM. The effect of SFN on cell proliferation and survival of IL-
3-growing Ba/F3 cells was also monitored (Figures 2B and S1).
Like TSA, SFN affected cell growth and viability in a dose-
dependent manner. Ba/F3 cells cultured for 24 and 48 hours in
the presence of 5 mM SFN stopped dividing (Figure 2B) and
partially died (30% dead cells monitored upon trypan blue
staining; Figure S1) while cells grown in 0.5 mM SFN showed
limited inhibition of cell proliferation and no cell death (Figures 2B
and S1 respectively). Ba/F3 cells grown in the presence of 100 nM
TSA stopped dividing and died, whereas strong cell growth
inhibition but limited cell death was monitored at 10 nM TSA
(Figures 2B and S1).
Sulforaphane treatment inhibits constitutive STAT5
activity in transformed cell lines
To further characterize the effect of SFN on STAT5 signaling,
expression of a series of STAT5 target genes (Cis, c-Myc, Pim-1,
Socs-1, Osm) and STAT5-independent genes (JunB, c-Fos, 36b4) was
analyzed in cells showing regulated STAT5 activity (IL-3-
stimulated Ba/F3 cells) and cells transformed upon expression of
constitutive active STAT5 (Ba/F3-1*6, K562). Ba/F3-1*6 cells
stably express a mutant form of mouse STAT5A (so-called 1*6)
carrying two amino acids substitutions which result in constitutive
STAT5 phosphorylation, nuclear localization and transactivation
properties [68]. Expression of STAT5A-1*6 confers IL-3-inde-
pendent growth to Ba/F3 cells in vitro and tumorigenicity to bone
marrow cells in vivo [68,70]. In the absence of IL-3, the upstream
activating kinase JAK2 is not activated [25,68]. Therefore,
pathways downstream of JAK2, such as MAPK and AKT
STAT5 Nuclear Activity Is Inhibited by Sulforaphane
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Figure 1. Sulforaphane (SFN) treatment inhibits IL-3-mediated induction of STAT5 target genes in Ba/F3 cells in a dose-dependent
manner. (A) Structure of the natural compound sulforaphane (SFN) and of the synthetic deacetylase inhibitor trichostatin A (TSA) used in this study.
(B) Ba/F3 cells were pre-treated 30 minutes with DMSO (vehicle), 0.2 mM TSA, 0.4, 2 or 10 mM SFN and further stimulated 30 minutes with 5 ng/mL IL-
3. Following cell harvest, expression of the STAT5 target genes Cis, Osm, c-Myc and of the housekeeping gene 36b4 were measured by quantitative
RT-PCR, as described in Materials and Methods. Similarly to TSA, SFN inhibits IL-3-mediated induction of STAT5-regulated genes.
doi:10.1371/journal.pone.0099391.g001
Figure 2. Effect of SFN treatment on cytotoxicity and viability of normal (Ba/F3) and transformed (Ba/F3-1*6, K562) cells. (A) The
WST-1 reagent was added to cells following 30 minutes of pre-treatment with 0.001, 0.01, 0.1 and 1 mM TSA or with 0.1, 1, 10 and 100 mM SFN. IL-3
(5 ng/mL) was supplemented to rested Ba/F3 cells at the same time as the WST-1 reagent to mimic the IL-3 stimulation conditions used in other
assays. OD measurement was performed after 90 minutes incubation with the WST-1 reagent, and the percentage of cytotoxicity was normalized to
the vehicle control. (B) Growing Ba/F3, Ba/F3-1*6 and K562 cells were incubated for 24 and 48 hours in the presence of the indicated concentrations
of TSA and SFN. Cell viability was measured by Trypan Blue exclusion assay.
doi:10.1371/journal.pone.0099391.g002
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[57,58], are not activated in Ba/F3-1*6 cells, in contrast to IL-3-
stimulated Ba/F3 cells. The mechanism of constitutive activation
of STAT5A-1*6 is unclear. Constitutive phosphorylation by basal
JAK2 activity or by an unidentified tyrosine kinase, and increased
stability of phospho-STAT5A-1*6 have been proposed to
contribute to its constitutive activity [25,68]. The human K562
leukemia cell line expresses a constitutively active BCR-ABL
tyrosine kinase. BCR-ABL oncogenic fusion constitutively phos-
phorylates STAT5 proteins, directly contributing to oncogenesis
[71–73].
First, the effect of SFN on cytotoxicity and cell viability of Ba/
F3-1*6 and K562 cells was evaluated, as done before in Ba/F3
cells (Figures 2 and S1). SFN-mediated cytotoxicity in Ba/F3-1*6
and K562 cells was comparable to that observed in Ba/F3 cells
and only detectable at a concentration of 100 mM (Figure 2A). The
effect of SFN and TSA on cell proliferation and survival was
comparable in the STAT5-1*6-transformed Ba/F3 cells and in the
untransformed parental cell line Ba/F3. The human leukemic cell
line K562 exhibited a reduced sensitivity to both SFN and TSA as
revealed by the limited effect on cell proliferation and cell death
(Figures 2B and S1).
Ba/F3, Ba/F3-1*6 and K562 cells were treated with vehicle,
0.2 mM TSA or 10 mM SFN for 90 minutes. After 30 minutes of
inhibitor pre-treatment, Ba/F3 cells were additionally stimulated
60 minutes with IL-3. K562 cells were also treated with 1 mM
Imatinib, a specific inhibitor of the BCR-ABL tyrosine kinase, as a
positive control for inhibition of constitutive STAT5 phosphory-
lation in K562 cells [74]. Expression of STAT5 target genes (Cis, c-
Myc, Pim-1, Socs-1, Osm), of JAK2/MAPK-regulated STAT5-
independent genes (JunB, c-Fos) [75,76], and of a housekeeping
control gene (36b4) was evaluated by quantitative RT-PCR
(Figure 3).
As predicted upon expression of constitutively active STAT5-
1*6 [21,25], expression of all STAT5 target genes investigated was
up-regulated to various extents in growing Ba/F3-1*6 cells in
comparison to unstimulated Ba/F3 cells (Figure 3A–B). As
anticipated, expression of all STAT5 target genes was inhibited
by TSA in all three cell lines (Figure 3A–C), as was expression of
Cis and c-Myc in Imatinib-treated K562 cells (Figure 3C). Likewise,
expression of all STAT5-target genes investigated was inhibited by
SFN in Ba/F3, Ba/F3-1*6 and K562 cells, demonstrating that
SFN is able to inhibit both regulated and constitutive STAT5
activity.
The specificity of action of SFN was further assessed by
monitoring expression of the MAPK-regulated genes JunB and c-
Fos. While expression of JunB and c-Fos was induced by IL-3 in
Ba/F3 cells, their expression remained at background levels in Ba/
F3-1*6 cells (Figure 3A-B), as expected from the absence of JAK2/
MAPK activation in Ba/F3-1*6 cells [25]. Interestingly, expres-
sion of JunB and c-Fos was differentially affected by SFN in IL-3-
stimulated Ba/F3 cells. While c-Fos expression remained unaffect-
ed, expression of JunB was reduced upon SFN treatment
(Figure 3A). This contrasts with the effect of TSA which did not
affect JunB expression while up-regulating c-Fos expression, in
agreement with our previous data [21]. The observation that
expression of JunB but not c-Fos is affected by SFN suggests that it
does not target the JAK2/MAPK pathways itself. This is
comforted by the observation that JunB basal expression in Ba/
F3-1*6 cells was also reduced upon SFN treatment (Figure 3B).
The observation that SFN and TSA exert both redundant and
non-redundant effects on gene expression also suggest that they
exhibit overlapping but also distinct activities.
Sulforaphane treatment does not alter STAT5
phosphorylation
To C pathway is inhibited by SFN, the phosphorylation status
of STAT5 was evaluated in Ba/F3, Ba/F3-1*6 and K562 cells
treated with SFN. STAT5 proteins are encoded by two highly
related genes, STAT5A and STAT5B, with both redundant and
unique functions [22,24]. STAT5 phosphorylation and STAT5A
and STAT5B protein levels were investigated by Western blot
using a phospho-STAT5-specific antibody (pSTAT5), and
STAT5A- and STAT5B-specific antibodies respectively
(Figure 4). Ba/F3, Ba/F3-1*6 and K562 cells were treated with
0.2 mM TSA or 0.4–10 mM SFN for 60 minutes. After 30 minutes
of inhibitor pre-treatment, Ba/F3 cells were stimulated 30 minutes
with IL-3. Ba/F3-1*6 and K562 cells were also treated with 1 mM
Imatinib, as a positive control for pSTAT5 inhibition in K562
cells. The BCR-ABL inhibitor Imatinib drastically and specifically
inhibited STAT5 phosphorylation in K562 cells (Figure 4C), as
previously reported [56,74]. In agreement with our previous data
in Ba/F3 cells [21], TSA did not affect STAT5 phosphorylation in
any of the three cell lines (Figure 4A–C). Likewise, SFN treatment
had no effect on STAT5 phosphorylation or on STAT5A/B
protein levels (Figure 4A–C). These results indicate that, similarly
to TSA, SFN does not inhibit the initial activation of STAT5 and
rather suggest a downstream inhibitory event. Consequently, we
analyzed the effect of SFN treatment on STAT5-mediated
transcription.
Sulforaphane treatment inhibits STAT5-mediated
transcriptional activity
We previously showed that the deacetylase inhibitor TSA
inhibits STAT5-mediated transcription at a step subsequent to
STAT5 binding to its target genes by preventing recruitment of
the transcriptional machinery [21]. Chromatin immunoprecipita-
tion assays were performed from TSA- and SFN-treated Ba/F3
cells, using antibodies directed against STAT5 and RNA
polymerase II proteins. Co-precipitated DNA was examined by
quantitative PCR using primers specific for the STAT5 binding
sites and transcription start sites respectively of the STAT5 target
genes Cis and Osm (Figure S2). The mouse Cis and Osm genes are
well characterized STAT5 target genes, bearing four and two
STAT5 binding sites respectively within their proximal promoter
[21,24,65,77,78] (Figure S2). Pre-treatment of Ba/F3 cells with
10 mM and 20 mM SFN, while leading to reduced Cis mRNA
levels, did not affect STAT5 binding or RNA polymerase II
recruitment to the Cis gene (Figures 5A–C and S3A). The Osm
gene which is more strongly inhibited by SFN at the mRNA level
displayed a partial but dose-dependent decrease in STAT5 and
RNA polymerase II recruitment upon SFN treatment (Figures 5A–
C and S3B). The marginal effect of SFN on STAT5 association
with DNA is similar to that of TSA on the same target genes [21]
(Figure S3). However, the absence or modest effect of SFN on
RNA polymerase II recruitment at Cis and Osm genes respectively
is in sharp contrast to the previously described effect of TSA,
which abolished RNA polymerase II recruitment at both target
genes [21] (Figure S3).
Impaired recruitment of RNA polymerase II at the transcription
start site of the Osm gene correlates well with - und thus might
account for - the observed reduction in Osm mRNA level. In
contrast, the unchanged occupancy of RNA polymerase II at the
transcription start site of the Cis gene suggests a further
downstream inhibitory event. Transcription is controlled at
multiple levels. The RNA polymerase II (Pol II) recruitment step
is followed by another critical regulatory event known as
STAT5 Nuclear Activity Is Inhibited by Sulforaphane
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promoter-proximal Pol II pausing, and subsequent promoter
escape into productive elongation [79–82]. Promoter-proximal Pol
II pausing is typically found at transcriptionally active and rapidly
induced genes and is characterized by a higher RNA polymerase
II density at the 59 end of the gene [79–81]. To investigate
whether SFN might interfere with transcription elongation, RNA
polymerase II occupancy along the open reading frame of the Cis
gene was monitored by chromatin immunoprecipitation and
quantitative PCR analysis of amplicons spread along the mouse
Cis gene locus (Figure 5D). Upon IL-3 stimulation, RNA
polymerase II was uniformly distributed along the Cis open
reading frame (+261 to +4029) with an increased occupancy
around the transcription start site (218/+55) (Figure 5D),
indicative of promoter-proximal Pol II pausing. In Ba/F3 cells
pre-treated with SFN, RNA polymerase II remained evenly
distributed along the Cis transcribed region, arguing against
abortive transcription elongation. However, the level of RNA
polymerase II, although unchanged at the transcription start site,
was slightly but consistently and reproducibly reduced throughout
the transcribed region (22% to 49% reduction depending on the
amplicon analyzed) (Figures 5D and S4). This overall reduced Pol
II association with the Cis transcribed region might be indicative of
impaired promoter clearance. Whether the reduced Pol II
occupancy is sufficient to account for the reduced Cis mRNA
level observed in SFN-treated cells (47% reduction in mRNA
level; Figure 5A) remains however to be demonstrated.
Altogether, our chromatin immunoprecipitation experiments
reveal that both TSA and SFN inhibit transcription of STAT5
target genes at a step following the association of STAT5 with
DNA. However, while TSA is able to abrogate RNA polymerase
II recruitment to STAT5 target promoters, SFN only partially
impaired RNA polymerase II recruitment and/or promoter
clearance, therefore suggesting that both small-molecules inhibit
transcription through distinct mechanisms.
Histone acetylation is not affected in SFN-treated Ba/F3
cells
SFN was shown to inhibit histone deacetylase activity in various
cell lines [14,15,17,18]. In order to determine whether the
inhibitory effect of SFN on STAT5 activity involves inhibition of
histone deacetylase activity, the effect of SFN on global histone H3
and H4 acetylation in Ba/F3 cells was investigated. IL-3-growing
Ba/F3 cells were treated with 0.2 mM TSA or 10 mM SFN for
increasing periods of time up to 4 hours. Histone proteins from
whole-cell extracts were analyzed by Western blot using antibodies
specific for acetylated histone H3 and H4 and for total histone H3
(Figure 6). Treatment of Ba/F3 cells with TSA for as short as 15
minutes led to a detectable increase in histone H3 and H4
acetylation, which kept increasing over time. To our surprise,
treatment with 10 mM SFN had no effect on global histone H3
and H4 acetylation levels, even after 4 hours of treatment, which is
beyond the duration of SFN treatment in our gene expression
assays (Figure 6). Prolonged SFN treatment up to 48 hours
revealed a slight increase in histone H3 acetylation (3.4-fold of
untreated control; Figure S5).
Since SFN was shown to alter histone acetylation locally, in
particular at the p21 promoter [17,18], the level of histone H3 and
H4 acetylation at the promoters of the p21 gene as well as of the
Figure 3. SFN treatment inhibits STAT5 constitutive activity in the transformed cell lines Ba/F3-1*6 and K562. Ba/F3 (A), its
transformed counterpart Ba/F3-1*6 (B) and human leukemic K562 (C) cells were treated 90 minutes with DMSO (vehicle), 0.2 mM TSA, 10 mM SFN or
1 mM Imatinib. Ba/F3 cells (A) were stimulated with 5 ng/mL IL-3 for 60 minutes following 30 minutes of drug pre-treatment. Expression of STAT5-
dependent (Cis, c-Myc, Pim-1, Socs-1, Osm,) and -independent (JunB, c-Fos, 36b4) genes was analyzed by quantitative RT-PCR. Gene expression data
were normalized to cDNA levels derived from mouse ribosomal S9 (A, B) or human Lamin A/C (LMNA) (C) mRNAs. (A, B) The Y-axis scales were
adjusted to allow a direct comparison of relative expression levels in Ba/F3 and Ba/F3-1*6 cells.
doi:10.1371/journal.pone.0099391.g003
Figure 4. SFN treatment does not affect STAT5 phosphorylation. Ba/F3 (A), Ba/F3-1*6 (B) and K562 (C) cells were treated 60 minutes with
DMSO (vehicle) or the indicated concentrations of TSA, SFN or Imatinib. Ba/F3 cells (A) were stimulated with 5 ng/mL IL-3 for 30 minutes following 30
minutes of drug pre-treatment. Whole-cell Brij protein lysates were analyzed by Western blot using antibodies specific for phospho-STAT5 (pSTAT5),
STAT5A, STAT5B, STAT5A and B, and a-tubulin (loading control).
doi:10.1371/journal.pone.0099391.g004
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STAT5 target genes Cis and Osm was monitored by chromatin
immunoprecipitation (Figure S2). Ba/F3 cells were pre-treated
with 0.2 mM TSA or 10 mM SFN and stimulated with IL-3 as
before and subjected to chromatin immunoprecipitation using
antibodies specific for acetylated histone H3 and H4 and for total
histone H3. To better reflect changes in histone acetylation, and
because histone H3 occupancy itself changes upon drug treatment
and IL-3 stimulation (Figure S6), histone H3 and H4 acetylation
data were normalized to total histone H3 levels (Figure 7). Major
changes in histone H3 and H4 acetylation levels were observed at
Cis, Osm and p21 proximal promoter regions upon TSA treatment
(Figure 7), in agreement with the global effect of TSA on histone
acetylation (Figure 6). In fact histone H3 occupancy itself was
greatly affected by TSA, especially at the promoters of
unstimulated genes (Figure S6). By contrast, no apparent
modifications in histone acetylation (Figure 7) or histone associ-
ation (Figure S6) at the investigated gene loci were noticeable in
SFN-treated cells.
In the whole, while treatment of Ba/F3 cells with TSA resulted
in changes in histone acetylation and association at the investi-
gated genes, no such changes were detectable upon SFN
treatment. Together with the observation that RNA polymerase
II association and/or stability was also differentially affected by
both inhibitory agents, our data support the idea that TSA and
SFN inhibit transcription of STAT5 target genes through distinct
mechanisms.
Discussion
The natural isothiocyanate sulforaphane (SFN) is an acknowl-
edged cancer chemopreventive agent with multiple blocking and
suppressive activities. It has been reported that SFN might act by
inhibiting histone deacetylation. Since we showed before that
deacetylase inhibitors such as trichostatin A (TSA) can inhibit
STAT5-mediated transcription [21], we investigated here whether
SFN can also inhibit STAT5 activity, possibly via inhibition of
deacetylase activity. We now show that, similarly to TSA, SFN
treatment reduces the expression of STAT5 target genes at the
RNA level in normal and cancer cells. Like TSA, SFN does not
target STAT5 phosphorylation or binding of activated STAT5 to
DNA, supporting a model in which both small-molecule inhibitors
target STAT5 transcriptional activity (Figure 8). Unlike TSA
however, SFN only modestly affected the recruitment of RNA
polymerase II to the promoter of STAT5 target genes. Impor-
tantly, as opposed to TSA, no significant changes in histone
acetylation were noted in cells treated with SFN, neither globally
nor locally at specific promoters. Our data therefore suggest that
inhibition of STAT5-mediated transcription by SFN is indepen-
dent of its activity as deacetylase inhibitor.
Our finding that histone acetylation was not changed upon SFN
treatment was unexpected and might appear inconsistent with
published reports of SFN-induced increase in histone acetylation
both globally and at specific promoters such as p21 [17,18,20]. We
believe that this apparent discrepancy might be due partly to the
difference in treatment duration and to the cellular context in both
types of studies. Given that our study is focusing on the short-term
effect of SFN on the regulation of STAT5 activity, exposure of
cells to SFN was limited to 60-90 minutes for gene expression
analyses and 4 hours for global histone acetylation determination
in Ba/F3 cells. The investigation of histone acetylation levels by
Myzak and colleagues was performed following 47 hours of
treatment with 15 mM SFN [17,18]. Longer treatment might be
necessary for sufficient accumulation of the SFN metabolites SFN-
cysteine and SFN-N-acetylcysteine, the active histone deacetylase
inhibitors, via the mercapturic acid pathway [15,17]. This would
explain why we observed no immediate effect of SFN on histone
acetylation levels, as opposed to that of TSA. In support of this
hypothesis, a 48-hour treatment of Ba/F3 cells with 10 mM SFN
led to a 3.4-fold increase in histone H3 acetylation, although
histone H4 acetylation was not increased in the same conditions.
On the other hand, a 48-hour treatment of Ba/F3 cells with
10 nM TSA resulted in a 44- and 25-fold increase in histone H3
and H4 acetylation respectively. This major difference in the effect
of TSA and SFN in Ba/F3 cells contrasts with the observations
made in the human prostate cell lines BPH-1, LnCaP and PC-3
and in the HEK 293 cells, showing comparable effects of TSA and
SFN on histone acetylation, in that case using TSA concentrations
30-times higher than in the present study [17,18]. This strongly
suggests that part of the activity of SFN as a deacetylase inhibitor is
Figure 5. STAT5 binding and RNA polymerase II recruitment to the promoter of STAT5 target genes are marginally affected by SFN
treatment. Ba/F3 cells were pre-treated 30 minutes with DMSO (vehicle), 10 mM or 20 mM SFN and further stimulated with 5 ng/mL IL-3 for 30
minutes. Cells were harvested for both gene expression analysis of the Cis and Osm genes by quantitative RT-PCR (A) and for chromatin
immunoprecipitation (ChIP) (B–D). ChIP was performed using antibodies directed against STAT5 (B) or RNA polymerase II (RNA Pol II; C, D) proteins.
Co-precipitated genomic DNA was analyzed by quantitative PCR using primers specific for the STAT5 binding sites (amplicons A and I in Figure S2)
(STAT5 ChIP; B) or the transcription start site (amplicons B and J in Figure S2) (RNA Pol II ChIP; C) of the mouse Cis and Osm genes, as well as with
primers spanning the open reading frame of the Cis gene (RNA Pol II ChIP; D). Schematic representation of the Cis gene with its transcribed region
(dark grey arrow), the coding sequence (white arrow with exons in light grey), the four STAT5 binding sites within its proximal promoter region, and
the quantitative PCR amplicons investigated (A to H-labeled black boxes) is shown in (D). The RNA polymerase II occupancy along the transcribed
region of the Cis gene is slightly but consistently reduced in SFN-treated cells. Two-tailed paired Student’s t-test, SFN-treated compared to vehicle
control (IL-3-stimulated); *P,0.05, **P,0.005, ***P,0.001, ****P,0.0001; ns, not significant.
doi:10.1371/journal.pone.0099391.g005
Figure 6. SFN treatment does not affect global histone
acetylation level in Ba/F3 cells. Ba/F3 cells were treated for the
indicated times with either 0.2 mM TSA or 10 mM SFN. Whole-cell
Freeze-Thaw protein lysates were analyzed by Western blot using
antibodies specific for acetylated histone H3 (Ac-H3) and H4 (Ac-H4)
and for total histone H3 proteins as a reference. While global histone
acetylation was markedly increased in cells treated with TSA, no
apparent effect was detected upon SFN treatment.
doi:10.1371/journal.pone.0099391.g006
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cell type-dependent and might not be highly relevant in Ba/F3
cells. We cannot exclude at this point that SFN alters STAT5
activity by modulating acetylation of non-histone proteins.
Notably, STAT5 proteins can be acetylated on specific lysine
residues, hence modifying their transcriptional activity [28,29].
Recent data from our laboratory suggest, however, that acetyla-
tion of STAT5 does not modulate its activity in Ba/F3 cells
(manuscript in preparation), making it unlikely that SFN-mediated
inhibition of STAT5 activity involves direct alteration of its
acetylation status.
Nonetheless, our data revealed a novel function of SFN as
STAT5 inhibitor, possibly targeting its transcriptional activity at a
step following binding of activated STAT5 to DNA. The question
remains as to how SFN exerts this immediate inhibitory activity.
Sulforaphane is an electrophile that can potentially react with
thiols. SFN was shown to react with free sulfhydryl groups of
cysteine residues in a number of proteins and, in some cases, to
directly alter their function [8,10,11,83]. Therefore, it remains
possible that SFN reacts with cysteine residues within STAT5 or a
cofactor of STAT5, thereby affecting STAT5-mediated transcrip-
tion. On the other hand, it was shown that the uptake and
accumulation of SFN in the cell occur through conjugation with
intracellular glutathione (GSH), resulting in a transient drop in
intracellular GSH [12]. Other electrophilic natural compounds,
such as terpenes and chalcones, are known to react with and
provoke a temporary decrease in intracellular GSH. The resulting
mild oxidative stress was shown to trigger S-glutathionylation of
cysteines within transcription factors such as STAT3 or NF-kB,
thereby inhibiting their activity [84–87]. It is therefore tempting to
speculate that SFN, as an electrophile, might as well inhibit the
activity of STAT5 or of a STAT5-associated factor important for
Pol II recruitment and/or promoter clearance [82] via S-
glutathionylation. Further investigations will be necessary to
address these potential thiol-dependent activities.
It should be noted that, since the consequences of SFN
treatment on RNA polymerase II occupancy at the STAT5 target
genes investigated were not dramatic, we cannot yet exclude the
possibility that the observed decrease in STAT5 target gene
mRNA levels is the result of a post-transcriptional - rather than
transcriptional - effect. In support of this hypothesis, gene
expression profiling of SFN-treated human prostate cancer cells
identified an enrichment in genes involved in RNA post-
transcriptional modification [88].
We showed that expression of JunB, was also inhibited by SFN
in Ba/F3 cells stimulated with IL-3. By contrast, the deacetylase
inhibitor TSA did not affect expression of JunB, as previously
reported [21]. JunB and c-Fos are known MAPK-regulated genes
[75,76]. Accordingly, expression of JunB and c-Fos was induced in
IL-3-stimulated Ba/F3 cells but not in Ba/F3-1*6 cells in the
absence of JAK2/MAPK activation. A variety of opposite effects
Figure 7. SFN treatment does not affect histone acetylation at the promoters of STAT5 target (Cis, Osm) and control (p21) genes. Ba/
F3 cells were pre-treated 30 minutes with DMSO (vehicle), 0.2 mM TSA or 10 mM SFN and further stimulated 30 minutes with 5 ng/mL IL-3. Chromatin
immunoprecipitation (ChIP) was performed using antibodies directed against acetylated histone H3 (Ac-H3) and H4 (Ac-H4) and against histone H3
proteins (total H3). Co-precipitated genomic DNA was analyzed by quantitative PCR using primers specific for the transcription start sites of the
mouse Cis (A) and Osm (B) genes (amplicons B and J respectively in Figure S2), as well as for the proximal promoter region of the mouse p21 gene
(amplicon K in Figure S2) as a control (C). Ac-H3 and Ac-H4 ChIP data were normalized to total Histone H3, to more accurately estimate histone
acetylation levels at the investigated gene loci. Corresponding raw ChIP data for Ac-H3, Ac-H4 and H3 immunoprecipitations (expressed as % of input
DNA) are shown in Figure S6. While histone acetylation levels were dramatically affected by TSA at all three gene loci, no major change in histone H3
and H4 acetylation was monitored in SFN-treated cells.
doi:10.1371/journal.pone.0099391.g007
STAT5 Nuclear Activity Is Inhibited by Sulforaphane
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e99391
of SFN on the regulation of the MAPK pathway has been
reported, mostly depending on the cell lines used and the
concentration of SFN applied [5,89–94]. However, since c-Fos
expression was not affected by SFN in IL-3-stimulated Ba/F3 cells,
it is unlikely that SFN inhibits the JAK2/MAPK pathway in Ba/
F3 cells. Moreover, basal expression of JunB in Ba/F3-1*6 cells
was also down-regulated by SFN, suggesting that the activity of
another factor involved in JunB basal transcription is targeted by
SFN. Beside the MAPK pathway, JunB expression is regulated by
various signaling pathways and transcription factors [95–99]. In
line with the proposed activity of SFN as an electrophile, it is
envisageable that SFN alters the activity of a factor essential for
JunB - but not c-Fos - expression.
In conclusion, we identified SFN as a novel STAT5 inhibitor,
likely targeting STAT5-mediated transcription independently of
its proposed action as an inhibitor of histone deacetylation
(Figure 8). Interestingly, the inhibitory effect of SFN was also
demonstrated in cell lines transformed by constitutive active
STAT5, therefore suggesting a beneficial role of the natural
isothiocyanate SFN not only in cancer prevention but also for
patients with STAT5-associated cancers.
Supporting Information
Figure S1 Effect of SFN treatment on Ba/F3, Ba/F3-1*6
and K562 cell death. Growing Ba/F3, Ba/F3-1*6 and K562
cells were incubated for 24 and 48 hours in the presence of the
indicated concentrations of TSA and SFN. Cell death was
measured by Trypan Blue exclusion assay and was expressed as
the percentage of dead cells. The number of living cells at 24 and
48 hours of treatment from the same experiment is presented in
Figure 2B.
(TIF)
Figure S2 Schematic representation of the genes and
PCR amplicons investigated by chromatin immunopre-
cipitation. The STAT5 target genes Cis and Osm carry four and
two STAT5 binding sites within their proximal promoters
respectively. Amplicons A (2188/2104) and I (2184/2122)
overlapping the STAT5 binding sites of Cis and Osm respectively
served for the detection of the chromatin co-precipitated with
STAT5 antibodies. Amplicons B (218/+55) and J (+25/+87)
overlapping the transcription start sites of Cis and Osm respectively
served for the detection of the chromatin co-precipitated with
RNA polymerase II antibodies. Amplicons B (Cis), J (Osm) and K
(p21; 2120/261) were used following chromatin immunoprecip-
itation with histone-specific (Ac-H3, Ac-H4, H3) antibodies.
Additional Cis amplicons are shown in Figure 5D. The transcribed
regions (dark grey arrow) of Cis, Osm and p21 are not represented
at their respective proportional scale.
(TIF)
Figure S3 In contrast to TSA, SFN does not prevent
recruitment of RNA polymerase II to the promoter of
STAT5 target genes. Ba/F3 cells were pre-treated 30 minutes
with DMSO (vehicle), 0.2 mM TSA or 10 mM SFN and further
stimulated 30 minutes with 5 ng/mL IL-3. Chromatin immuno-
precipitation (ChIP) was performed as described in Materials and
Methods using antibodies directed against STAT5 or RNA
polymerase II (RNA Pol II) proteins. Co-precipitated genomic
DNA was analyzed by quantitative PCR using primers specific for
the STAT5 binding sites (STAT5 ChIP; amplicons A and I in
Figure S2) or the transcription start site (RNA Pol II ChIP;
amplicons B and J in Figure S2) of the mouse Cis (A) and Osm (B)
genes. While TSA treatment prevents recruitment of RNA
polymerase II following STAT5 binding to DNA, in agreement
with our published data [21], SFN treatment has only partial (Osm)
or no (Cis) effect on RNA polymerase II occupancy at the
transcription start site of STAT5 target genes. Two-tailed paired
Student’s t-test, SFN-treated and TSA-treated compared to
vehicle control (IL-3-stimulated); *P,0.05, **P,0.005, ***P,
0.001, ****P,0.0001; ns, not significant.
(TIF)
Figure S4 RNA polymerase II occupancy along the Cis
open reading frame is reproducibly reduced in SFN-
treated cells. Ba/F3 cells were pre-treated 30 minutes with
DMSO (vehicle), 10 mM (A) or 20 mM (B) SFN and further
stimulated with 5 ng/mL IL-3 for 30 minutes. Chromatin
immunoprecipitation (ChIP) was performed as described above
using antibodies directed against RNA polymerase II (RNA Pol
II). Co-precipitated genomic DNA was analyzed by quantitative
PCR using primers spanning the open reading frame of the Cis
gene (amplicons C-H, as schematized in the upper panel). Panels A
and B represent data from two independent experiments. Data
from panel B are the same as shown in figure 5B. Two-tailed
paired Student’s t-test, SFN-treated compared to vehicle control
(IL-3-stimulated); P values and their significance are indicated
above each pair; ns, not significant.
(TIF)
Figure 8. Model of inhibition of STAT5 activity by SFN in Ba/F3
cells. IL-3 binding to its receptor leads to activation of the receptor-
associated JAK2 tyrosine kinase. In turn, JAK2 activates the downstream
STAT5, MAPK and AKT pathways via phosphorylation (broad arrows),
resulting in induced transcription of downstream target genes (thin
arrows). We showed that, similarly to TSA, SFN inhibits induction of
STAT5 target genes without interfering with STAT5 initial activation
(phosphorylation) and binding to DNA. In contrast to TSA however, SFN
does not affect histone acetylation, neither globally nor locally at
specific gene loci, and only moderately interferes with recruitment of
the transcriptional machinery, suggesting an alternative mechanism of
transcriptional inhibition, independent of deacetylase activity. JunB
expression was also inhibited by SFN in Ba/F3 cells, although via a
MAPK-independent mechanism.
doi:10.1371/journal.pone.0099391.g008
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Figure S5 Prolonged treatment of Ba/F3 cells with SFN
results in increased histone H3 acetylation. Ba/F3 cells
were treated for the indicated times with either 10 nM TSA or
10 mM SFN. Whole-cell Freeze-Thaw protein lysates were
analyzed by Western blot using antibodies specific for acetylated
histone H3 (Ac-H3) and H4 (Ac-H4) and for total histone H3
proteins, as in Figure 6. To allow an accurate assessment of histone
acetylation levels, Western blots were repeated 4 times and
chemiluminescence signals were quantified using ImageQuant TL
(GE Healthcare). Ac-H3 and Ac-H4 signals were normalized to
total H3 and expressed relative to the untreated control (arbitrarily
set to 1; see values below each lane) (A). Means 6SD of relative
Ac-H3/H3 and Ac-H4/H3 values (fold of untreated control) from
the 4 blots shown in (A) are depicted in (B). Two-tailed paired
Student’s t-test, SFN-treated compared to untreated control; *P,
0.05. Treatment of Ba/F3 cells up to 48 hours with SFN resulted
in a global increase in acetylated histone H3 (3.4-fold) while
acetylated histone H4 level was slightly decreased (1.6-fold).
(TIF)
Figure S6 SFN treatment does not affect histone
acetylation at the promoters of STAT5 target (Cis,
Osm) and control (p21) genes (% input DNA). Ba/F3 cells
were pre-treated 30 minutes with DMSO (vehicle), 0.2 mM TSA
or 10 mM SFN and further stimulated 30 minutes with 5 ng/mL
IL-3. Chromatin immunoprecipitation (ChIP) was performed
using antibodies directed against acetylated histone H3 (Ac-H3)
and H4 (Ac-H4) and against histone H3 proteins (total H3). Co-
precipitated genomic DNA was analyzed by quantitative PCR
using primers specific for the transcription start sites of the mouse
Cis (A) and Osm (B) genes (amplicons B and J respectively in Figure
S2), as well as for the proximal promoter region of the mouse p21
gene (amplicon K in Figure S2) as a control (C). Ac-H3 and Ac-H4
ChIP data normalized to total Histone H3 are shown in Figure 7.
(TIF)
File S1 Raw data (Quantitative PCR CT values, WST-1
OD values).
(PDF)
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